Catalyst Dossier · compiled by CeliA 🧫
EAGLE PHARMACEUTICALS, INC. (EGRX)
Pharmaceutical Preparations · market cap $3M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CAL02 | Phase 2 | Pneumonia, Bacterial |
| Ryanodex and Standard of Care | Phase 3 | Exertional Heat Stroke |
| Dantrolene sodium for injectable suspension | Phase 2 | Heat Stroke |
| SeeMore(TM) | Phase 2 | Myocardial Infarction |
| Mesalamine | Phase 3 | Mild to Moderate Ulcerative Colitis |
Price & technical context
3-month
-80.8%
6-month
-92.2%
12-month
-78.8%
52-wk range
$0.10–$3.74
vs 50-day MA
-39.9%
vs 200-day MA
-86.8%
Realized vol
315.6%
Max drawdown
-98.5%
Daily closes through 2026-02-17. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EGRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.